Northern Trust Corp Decreases Holdings in Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Northern Trust Corp reduced its stake in AMNEAL PHARMACEUTICALS by 3.9% to approximately $14.32 million, holding 1,708,627 shares at the end of the quarter.
• AMNEAL PHARMACEUTICALS reported $0.23 EPS for the quarter, surpassing analysts' expectations of $0.17, while setting FY 2025 guidance at 0.700-0.750 EPS.
• Analysts have a consensus rating of "Buy"** on AMNEAL PHARMACEUTICALS, with a price target averaging $11.60.

Northern Trust Corp cut its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 3.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,708,627 shares of the company's stock after selling 68,656 shares during the quarter. Northern Trust Corp owned 0.55% of Amneal Pharmaceuticals worth $14,318,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Sei Investments Co. boosted its position in shares of Amneal Pharmaceuticals by 0.4% in the 1st quarter. Sei Investments Co. now owns 340,816 shares of the company's stock worth $2,710,000 after purchasing an additional 1,355 shares in the last quarter. Amalgamated Bank lifted its stake in shares of Amneal Pharmaceuticals by 33.0% in the first quarter. Amalgamated Bank now owns 5,511 shares of the company's stock worth $46,000 after buying an additional 1,367 shares in the last quarter. GF Fund Management CO. LTD. lifted its stake in Amneal Pharmaceuticals by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 7,934 shares of the company's stock worth $66,000 after purchasing an additional 1,428 shares in the last quarter. Xponance Inc. boosted its holdings in Amneal Pharmaceuticals by 16.1% in the 1st quarter. Xponance Inc. now owns 13,183 shares of the company's stock valued at $110,000 after purchasing an additional 1,828 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Amneal Pharmaceuticals by 3.3% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 90,460 shares of the company's stock worth $716,000 after purchasing an additional 2,911 shares during the last quarter. 31.82% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on AMRX shares. The Goldman Sachs Group assumed coverage on shares of Amneal Pharmaceuticals in a research report on Friday, June 6th. They set a "buy" rating and a $12.00 price objective on the stock. Wall Street Zen downgraded shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $11.60.

Insider Transactions at Amneal Pharmaceuticals

In related news, EVP Nikita Shah sold 6,340 shares of the stock in a transaction on Monday, August 25th. The stock was sold at an average price of $9.50, for a total transaction of $60,230.00. Following the completion of the sale, the executive vice president directly owned 146,403 shares in the company, valued at approximately $1,390,828.50. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jason B. Daly sold 22,000 shares of Amneal Pharmaceuticals stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total value of $199,100.00. Following the sale, the executive vice president directly owned 10,606 shares in the company, valued at approximately $95,984.30. This trade represents a 67.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 609,206 shares of company stock valued at $5,700,625 in the last three months. 17.45% of the stock is currently owned by insiders.

Amneal Pharmaceuticals Trading Up 0.2%

Shares of AMRX stock traded up $0.02 during trading hours on Monday, reaching $9.64. 778,019 shares of the company's stock were exchanged, compared to its average volume of 1,667,351. The stock has a market cap of $3.03 billion, a PE ratio of 962.46 and a beta of 1.19. The stock's fifty day moving average price is $8.67 and its two-hundred day moving average price is $8.13. Amneal Pharmaceuticals, Inc. has a 1 year low of $6.68 and a 1 year high of $9.80.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. On average, equities analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.